Click here to go to the previous page
The UK Drug Pipeline: A Leader in Drug Innovation
Program Code:
IS2120
Date:
Sunday, May 6, 2007
Time:
4:00 PM to 5:30 PM
CHAIR
:
Kevin Cox, President & CEO, Avecia Biologics
SPEAKER
(S):
Malcolm Wicks
Martin Postle, Director, Cambridge Healthcare & Biotech
Mark Ferguson, Chief Executive Officer, Renovo plc
Alan Smith, Chief Scientific Officer, Genzyme Corporation
Description
This session will present the UK's pipeline for the first time and demonstrate why UK is one of the most productive biotech countries in the world. A panel of leading British figures will present key innovations in the biotech sector and what the UK government is doing to support this key industry.
Objectives:
Demonstrate the extent of the UK's pipeline of drugs in clinical development, their indications and stages of development.
Discuss the sources of this innovation and the strengths in the UK's biotech R&D base.
Promote the opportunities for biotechs and pharmaceutical companies to partner with UK institutions and companies.